凯利泰(300326.SZ):对宁波深策的商誉计提约3.85亿元的减值准备
格隆汇 1 月 29日丨凯利泰(300326.SZ)公布,公司于2021年1月28日召开第四届董事会第二十五次会议、第四届监事会第二十一次会议,审议通过了《关于计提宁波深策胜博科技有限公司商誉减值准备的议案》。鉴于高值耗材集中采购的影响,经审慎评估,公司对宁波深策胜博科技有限公司(“宁波深策”)的商誉计提38508.99万元的减值准备。
公司本次计提宁波深策商誉减值准备38508.99万元,该项减值损失计入公司2020年度合并损益,相应公司2020年度合并报表归属于母公司所有者的净利润减少38508.99万元。公司预计2020年度归属于母公司所有者的净利润将出现较大亏损。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.